Symetis AG

Symetis AG  

Symetis is a privately held Swiss biotechnology company developing innovative, tissue-engineered, autologous heart valves for the replacement of malformed or malfunctioning heart valves. Symetis produces an autologous, living heart valve within several weeks after receipt of the patient’s own vascular cells. In in-vivo studies, these tissue-engineered heart valves perform mechanically and biologically as a natural heart valve with the unique potential to grow when needed to adapt to the adjacent tissue. Year of foundation: 2001